AR127317A1 - Rna terapéutico para el cáncer de pulmón - Google Patents

Rna terapéutico para el cáncer de pulmón

Info

Publication number
AR127317A1
AR127317A1 ARP220102747A ARP220102747A AR127317A1 AR 127317 A1 AR127317 A1 AR 127317A1 AR P220102747 A ARP220102747 A AR P220102747A AR P220102747 A ARP220102747 A AR P220102747A AR 127317 A1 AR127317 A1 AR 127317A1
Authority
AR
Argentina
Prior art keywords
immunogenic
amino acid
acid sequence
variant
mage
Prior art date
Application number
ARP220102747A
Other languages
English (en)
Spanish (es)
Inventor
Ugur Sahin
David Weber
Carina Walter
Roldn Diana Barea
Ruprecht Kuner
Melanie Hein
Martin Suchan
Verena Kissler
Lena Mareen Kranz
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/078022 external-priority patent/WO2023061550A1/en
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of AR127317A1 publication Critical patent/AR127317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ARP220102747A 2021-10-11 2022-10-11 Rna terapéutico para el cáncer de pulmón AR127317A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2021/078022 WO2023061550A1 (en) 2021-10-11 2021-10-11 Therapeutic rna for lung cancer
EP2022050135 2022-01-05

Publications (1)

Publication Number Publication Date
AR127317A1 true AR127317A1 (es) 2024-01-10

Family

ID=84286153

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102747A AR127317A1 (es) 2021-10-11 2022-10-11 Rna terapéutico para el cáncer de pulmón

Country Status (11)

Country Link
US (1) US20240415946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415747A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537298A (cg-RX-API-DMAC7.html)
KR (1) KR20240099175A (cg-RX-API-DMAC7.html)
AR (1) AR127317A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022365280A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234915A1 (cg-RX-API-DMAC7.html)
IL (1) IL312026A (cg-RX-API-DMAC7.html)
MX (1) MX2024004421A (cg-RX-API-DMAC7.html)
TW (1) TW202333803A (cg-RX-API-DMAC7.html)
WO (1) WO2023061931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201659A1 (en) * 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054716A2 (en) * 2000-01-27 2001-08-02 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
AU2020395765A1 (en) * 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines

Also Published As

Publication number Publication date
CA3234915A1 (en) 2023-04-20
JP2024537298A (ja) 2024-10-10
TW202333803A (zh) 2023-09-01
US20240415946A1 (en) 2024-12-19
AU2022365280A1 (en) 2024-05-02
WO2023061931A1 (en) 2023-04-20
IL312026A (en) 2024-06-01
EP4415747A1 (en) 2024-08-21
KR20240099175A (ko) 2024-06-28
MX2024004421A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
CU20210097A7 (es) Arn terapéutico para cáncer de ovario
ECSP23054131A (es) Cocristal de un inhibidor de cdk
MX2020013068A (es) Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
AR118047A2 (es) Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica
CO2026004333A2 (es) Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
CR20170350A (es) Dinucleótidos cíclicos útiles en el tratamiento del cáncer
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20170198A1 (es) Dinucleotidos ciclicos como moduladores de sting
PE20210628A1 (es) Anticuerpos anti-cd73 y metodos de uso de los mismos
MX2024002725A (es) Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina.
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CR20200410A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
DOP2025000146A (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CU20210075A7 (es) Arn terapéutico para el cáncer de próstata
MX352892B (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
PE20180741A1 (es) Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
AR127324A1 (es) Rna terapéutico para el cáncer de pulmón

Legal Events

Date Code Title Description
FB Suspension of granting procedure